The United States of America, As Represented by the Secretary, Department of Health and Human Services

Applied Spectral Imaging Ltd.

The United States of America As Represented by the Department of Health

Thomas Ried

Dirk G Soenksen

Dario Cabib

Robert A Buckwald

Yuval Garini

Gert Auer

Jens Habermann

Catharina Larsson

Evelin Schrock

Kerstin Heselmeyer

Merryn Macville

Merryn V E MacVille

Anton H N Hopman

Sonia Andersson

Winfried Steinberg

Kerstin Heselmeyer-Haddad

Torsten Liersch

Heinz Becker

Marian Grade

Bijan-Michael Ghadimi

Michael J Difilippantonio

The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The invention further related to methods of identifying biomarker for determining colorectal cancer status in a subject.

Identification of biomarkers by serum protein profiling

A cDNA array (9984 genes) was used for expression profiling in rectal adenocarcinoma. The expression data were correlated to responsiveness to chemotherapy followed by radiotherapy. A set of 54 genes was found that were differentially expressed in responders vs. non-responders. The genes may be used as prognostic markers for determining whether a rectal adenocarcinoma is responsive to radiochemotherapy.

Composition for detecting the response of rectal adenocarcinomas to radiochemotherapy

The invention provides methods for identifying conditions of low grade cervical dysplasia and assessing the progressive potential of individual lesions to develop into high grade cervical dysplasia and cervical squamous cell cancer as well as cervical adenocarcinoma.

Method for detecting risk of progression of low grade cervical dysplasia

The present invention is directed to an improved method for detecting a genetic marker in a biological sample comprising contacting the biological sample with a nucleic acid probe linked to a detectable moiety, whereby the detectable moiety can be detected by the presence of a chromogenic dye associated with the detectable moiety, obtaining a spectral image of the biological sample using brightfield microscopy, and detecting the presence of the chromogenic dye, thereby detecting the genetic marker in the biological sample. The present invention also provides an improved method for detecting a phenotypic marker in a biological sample comprising contacting the biological sample with a compound comprising a detectable moiety, whereby the compound associates with the phenotypic marker and whereby the detectable moiety can be detected by the presence of a chromogenic dye associated with the detectable moiety, obtaining a spectral image of the biological sample using brightfield microscopy, and detecting the presence of the chromogenic dye, thereby detecting the phenotypic marker in the biological sample.

Methods for assessing genetic and phenotypic markers by simultaneous multicolor visualization of chromogenic dyes using brightfield microscopy and spectral imaging

A spectral imaging method for simultaneous detection of multiple fluorophores aimed at detecting and analyzing fluorescent in situ hybridizations employing numerous chromosome paints and/or loci specific probes each labeled with a different fluorophore or a combination of fluorophores for color karyotyping, and at multicolor chromosome banding, wherein each chromosome acquires a specifying banding pattern, which pattern is established using groups of chromosome fragments labeled with various fluorophore or combinations of fluorophores.

Method for simultaneous detection of multiple fluorophores for in situ

The invention provides a method of detecting the presence of invasive cervical carcinoma in a subject comprising detecting in a cervical cell from the subject the presence of a chromosome abnormality which is associated with invasive cervical carcinoma; the presence of the cervical cell containing the chromosome abnormality indicating the presence of invasive cervical carcinoma in the subject. The invention also provides a method of detecting the presence of advanced-stage cervical carcinoma in a subject comprising detecting in a cervical cell from the subject the presence of a chromosome abnormality associated with advanced-stage cervical carcinoma; the presence of the cervical cell containing the chromosome abnormality indicating the presence of advanced-stage cervical carcinoma in the subject. The invention also provides a method of classifying the progression of dysplastic cervical cells from a non-invasive cervical carcinoma to an invasive cervical carcinoma comprising analyzing the dysplastic cervical cells for the presence of a chromosome abnormality which is associated with invasive cervical carcinoma, and classifying the dysplastic cervical cells having the chromosome abnormality as having progressed from a non-invasive cervical carcinoma cells to an invasive cervical carcinoma. The invention further provides kits comprising nucleic acids that specifically hybridize to chromosome 3q and specifically hybridize to another chromosome, and to compositions comprising nucleic acids.

Methods for detecting cervical cancer

Growing community of inventors

Bethesda, MD, United States of America

Thomas Ried